M utations in >50 genes, mostly encoding sarcomeric and Z disc proteins, cause hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) that lead to heart failure.
M utations in >50 genes, mostly encoding sarcomeric and Z disc proteins, cause hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) that lead to heart failure. 1 Genetic variation in a Z disc gene can cause various forms of cardiomyopathies such as HCM or DCM perhaps because of pleiotropic effects on survival and hypertrophic pathways. 2 The muscle LIM protein (cysteine and glycinerich protein 3 [CSRP3] ) is a Z disc protein involved in cardiac mechanosensation that is important for myocyte-specific survival pathways through interactions with other Z disc proteins. [3] [4] [5] CSRP3 mutations have been found in both HCM and DCM patients, 3, 4, 6 and we used protein-protein interaction studies to identify new CSRP3-interacting partners that may be important for cardiac myocyte survival or cardiomyopathy.
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Methods
All primers and antibodies used are listed in Tables I to III in the Data Supplement. Tissue culture experiments were performed using primary neonatal and adult rat cardiac myocytes, and animal experiments were performed using conditional knockout (cKO-Zbtb17), overexpressing transgenic (TG-ZBTB17) and double-transgenic (TG-ZBTB17/KO-Ppp3cb) protein phosphatase 3, catalytic subunit, β isozyme (calcineurin Aβ, Ppp3cb) animals.
The procedures in animal studies have been followed in accordance with institutional guidelines. Human studies have been approved by an institutional review committee, and that the subjects gave informed consent.
Yeast 2-hybrid, Western blot, quantitative real-time polymerase chain reaction, and other assays were performed as described elsewhere. [3] [4] [5] 7 Statistical evaluations were performed by nonparametric Mann-Whitney U tests and unpaired Student t tests (more details are available in the Data Supplement).
Results
CSRP3 Interacts With ZBTB17
Yeast 2-hybrid screens using CSRP3 as bait 3 classified α-actinin and telethonin as CSRP3-interacting proteins that are important determinants of cardiac function 5, 8 and also identified ZBTB17 ( Figure 1A ). ZBTB17 is a member of the poxvirus and zinc-finger (POZ or BTB) domain/zinc-finger transcription factor family with no previously described role in the heart. 9 We confirmed the CSRP3-ZBTB17 interaction by coimmunoprecipitation in vivo ( Figure 1B ), cross-linking of recombinant proteins ( Figure 1C ), and immunohistochemistry studies ( Figure 1D ; Figure I in the Data Supplement). These data identify ZBTB17 as a novel CSRP3-interacting protein.
Analysis of a Human ZBTB17 Variant (T106M)
ZBTB17 is encoded on human chromosome 1 at the replicated 1p36 cardiomyopathy locus. [10] [11] [12] The peak DCM association at this locus (rs10927875; P=1.3×10
12 is located in intron 2 of ZBTB17, with further evidence of association of this single nucleotide polymorphism with DCM in Chinese population. 12, 13 Considering rare polymorphisms (allele frequency <0.1%; population prevalence of cardiomyopathies ≈1:500 1 ), we identified a p.T106M variant in the Exome Variant Server. The p.T106M variant could not be stably expressed in cardiac myocytes (Figure 2A ), bound poorly to CSRP3 ( Figure 2B ), caused structural abnormalities to the POZ domain ( Figure 2C and 2D), and may represent a rare haploinsufficient polymorphism. Together, these data point to ZBTB17 as a possible disease gene at the 1p36 cardiomyopathy locus and suggest a role for a transcription factor in heart failure, as recently shown for left ventricular non compaction cardiomyopathy.
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Analysis of ZBTB17 Function In Vitro
To study function in vitro, we overexpressed ZBTB17 in cardiac myocytes and found that it induced hypertrophy (Figure 3A and 3B; Figure IIA in the Data Supplement). CSRP3 and other CSRP3-interacting proteins have important roles in cardiac myocyte survival, and this was also observed for ZBTB17 ( Figure 3C ; Figure IIB in the Data Supplement). Calcineurin activity is of central importance for prohypertrophic signaling and myocyte survival, 15, 16 and in both the hypertrophy and the cell death experiments inhibition of calcineurin attenuated the effects of ZBTB17, suggesting an interaction ( Figure 3A and 3C) . Hence, ZBTB17 regulates cardiac hypertrophy and cell survival, a recognized dual-property of genes that are of central importance for cardiac myocyte biology.
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Analysis of ZBTB17 Function In Vivo
Mice with global deletion of Zbtb17 die because of a gastrulation defect. 19 Therefore, we crossed floxed Zbtb17 mice 20 with the MLC2v Cre deleter line 21 to test Zbtb17 gene function in cardiac myocyte-specific cKO ( Figure 3A -3D in the Data Supplement). cKO mice were viable and, in the absence of a spontaneous functional cardiac phenotype, we used the established model of transverse aortic constriction (TAC) 5 to unveil potential gene effects. After TAC, the left ventricles of cKO mice became dilated and exhibited impaired contractile performance, which are the cardinal features of DCM (Table 1) . When compared with controls, failing cKO hearts had higher apoptotic events (8.5-fold; P<0.001), increased activated caspase 3 (6.3-fold; P<0.001), and marked replacement fibrosis ( Figure 4A ; Figure IIIE and Table II in the Data Supplement). These data show that Zbtb17 modulates biomechanical stress-induced apoptosis and interstitial fibrosis in vivo, which are important in the pathobiology of both HCM and DCM.
To begin to understand the molecular mechanisms by which ZBTB17 regulates cardiac myocyte survival, based on the functions of ZBTB17 in other tissues, 19 we combined our microarray data with apoptosis-specific gene expression array analysis (quantitative real-time polymerase chain reaction based, n=84) in cKO.TAC and control.TAC mouse hearts. We used Gene Set Enrichment Analysis 22 to test whether differentially expressed genes by genome-wide microarray analysis were significantly enriched in the set of differentially expressed genes detected by apoptosis-specific quantitative real-time polymerase chain reaction array analysis and found significant concordance for a set of 8 genes (P<0.05, false discovery rate, <1%; Table 2 ). Among these, the proapoptotic genes were consistently upregulated in cKO, whereas the antiapoptotic genes, Nol3 and Tnfrsf1a, were downregulated in cKO hearts after biomechanical stress, supporting a role for Zbtb17 in the regulation of apoptosis. Six of 8 differentially expressed genes were also detected by ChIP-chip analysis to have binding sites (Table 2) . Hence ZBTB17 regulates a transcriptional program that protects cells against apoptosis.
In addition, ZBTB17 overexpression drives hypertrophy in vitro ( Figure 3 ). To examine further the effects of ZBTB17 on hypertrophy we overexpressed ZBTB17 in mice using a cardiac myocyte-specific promoter 23 ( Figure IV in the Data Supplement ). Transgenic mice (TG-ZBTB17) exhibited spontaneous cardiac hypertrophy with enlarged cardiac myocytes and increased Nppa expression (Table I in the Data Supplement ; Figure 4B and 4C). In vitro experiments suggested a link between ZBTB17 and calcineurin, and ChIPchip data showed binding of ZBTB17 to the calcineurin Aβ (Ppp3cb) promoter that we confirmed by ChIP quantitative real-time polymerase chain reaction and reporter assays ( Figure 4D and 4E). There was increased expression of Ppp3cb and Nfatc2 in TG-ZBTB17 hearts and decreased expression in cKO ( Figure 4F ; Figure VA in the Data Supplement). We crossed ZBTB17 transgenic mice into a Ppp3cb-deficient 6 clones were screened, and 650 positive clones were identified, 3 one of which encoded the 5′ sequence of Zbtb17. B, Immunoprecipitation of ZBTB17 from heart lysates results in the coprecipitation of CSRP3. Input indicates mouse heart extract, a Csrp3 antibody (sc-30274; Santa Cruz Biotechnology) has been used for immunoprecipitation, and a well-characterized Zbtb17 (Santa Cruz H-190; sc 22837) antibody has been used to detect the protein. No antibody or an unrelated anti-Kir2.1 antibody served as negative controls. C, Cross-linking experiments of recombinant proteins confirm binding between ZBTB17 and CSRP3. Top, With increasing concentration of cross-linking reagent, the individual components decrease, whereas a large complex emerges. The complex contains multiple copies of each protein reflecting the oligomeric nature of the individual components. Bottom left, Positive control showing cross-linking between CSRP3 and Telethonin (TCAP), a known interaction. Bottom right, Negative controls: we attempted to cross-link CSRP3 separately with 2 different proteins that have no documented association but are known to cross-link well to their binding proteins. These were small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA) and HLA-B associated transcript 3 (BAT3). As expected, increasing cross-linking reagents showed no binding between CSRP3 and the negative control proteins, but only the usual CSRP3 oligomers indicated with stars. D, Colocalization of ZBTB17 and CSRP3 in the nuclei of human cardiac myocytes. Arrows indicate typical cardiac myocyte nuclei that are positive for both ZBTB17 and CSRP3. Lower left, Three-dimensional image of the boxed region (left middle). Lower right, Three-dimensional colocalized color intensity image of ZBTB17 with CSRP3: mean percentage of nuclear ZBTB17 colocalized with nuclear CSRP3=79.4±5.5%; mean Pearson coefficient of colocalized volumes=0.88 (n=4, ≈125 nuclei per heart).
background that prevented cardiac myocyte hypertrophy and decreased Nppa expression, confirming the interaction of ZBTB17 with the calcineurin pathway ( Figure 4B ; Table I in the Data Supplement ).
Discussion
CSRP3 mutations cause heart failure in various animal models 4, 24 and have been identified in various patients affected by DCM 3, 25 or HCM. [26] [27] [28] Although many cardiomyopathy and heart failure models have been developed, the molecular mechanisms that link sarcomeric and Z disc proteins to these phenotypes remain not well understood. Here, we show that CSRP3 interacts with ZBTB17 and provide the first detailed analysis of this transcription factor in the cardiovascular system. In particular, we demonstrate that ZBTB17 causes cardiac myocyte hypertrophy and is essential for cell survival. The extent of hypertrophy in cardiac myocytes is comparable with the effects seen with trophic signals including mitogenic serum in these postmitotic cells. 29, 30 To date, ZBTB17 is the only known transcription factor to interact with CSRP3 and to be expressed in cardiac myocytes. 31 The effects of ZBTB17 on hypertrophy and survival are not only restricted to the in vitro situation but also observed in genetically altered animals under in vivo conditions. Interestingly, ZBTB17-overexpressing transgenic animals did not develop heart failure because of massive increase in apoptosis as frequently seen in other genetically altered mouse models. [32] [33] [34] [35] The combination of ChIP-chip, whole-gene expression, and apoptosis array data clearly point to an important role of ZBTB17 in orchestrating a cardioprotective gene expression 
C, NMR1H-
15 N HSQC spectrum of WT (red) and T106M (black) ZBTB17-POZ domain with pertinent residues assigned based on predicted chemical shift. The mutation causes significant structural disruption to the POZ domain. D, The available ZBTB17-POZ structure was used to model the T106M mutation. Fifty nanoseconds of simulation of the WT and the T106M structures that have been run as the full quadrameric structures as in the PDB 2Q81. Red indicates the native and yellow the mutant ZBTB17, spheres represent the T and M residues. It can be clearly seen that the structures of the α-6, where the mutation is located, have changed. Also the simulations reveal that there is a much higher level of structural mobility for the mutant case. The mutation causes significant structural disruption to the POZ domain, a finding consistent with our NMR data, arrowheads indicate position 106, arrows indicate a position far away).
program. This is indicated by the fact that proapoptotic genes were consistently upregulated, whereas antiapoptotic genes were downregulated in cKO hearts after biomechanical stress (Table 3) .
We also show that ZBTB17 targets various calcineurin/ NFAT genes and activates this pathway. This notion is supported by our whole-gene expression analysis, ChIP-chip assays, analysis of the calcineurin/NFAT pathway activation, promoter assays, and by the significant loss of hypertrophy when TG-ZBTB17 animals are crossed into the calcineurin Aβ-deficient background (Figures 3 and 4D and 4E ). These data are also supported by our finding of enhanced calcineurin Aβ and Nfatc2 mRNAs in hearts of ZBTB17 transgenic animals and decreased calcineurin Aβ and Nfatc2 mRNAs in hearts of Zbtb17 cKO animals after TAC ( Figure 4F ; Figure  VA in the Data Supplement).
CSRP3 translocates into the nucleus on TAC 36 and is essential for the adaptation of cardiac myocytes to biomechanical stress. 37 CSRP3, like telethonin, is primarily expressed in muscle tissues. By interacting with ZBTB17, CSRP3 plays a role in the initiation of myocyte-specific survival pathways or mechanoptosis (mechanosensitive types of cell death 5 ). This notion is supported by the fact that Csrp3-deficient hearts exhibit increased rates of apoptosis, 38 hence the interaction of CSRP3 with ZBTB17 can also be described as a form of Z disc transcriptional coupling. 39 Calcineurin/NFAT signaling is an important mediator of cardiac hypertrophy, 40, 41 and this pathway is also known to exert cardioprotective effects by avoiding apoptosis during ischemia reperfusion, 15 which emphasizes the effects of ZBTB17 on cell survival.
CSRP3 directly interacts with calcineurin and is required for its activation, 42 thus by interacting with ZBTB17; CSRP3 introduces an additional level of control, which ensures an intermediate level of calcineurin/NFAT activation ( Figure 4G ). For a long time, c-myc is known to be induced during TAC, 43 but its downstream effects in cardiac myocytes remained elusive. However, c-myc is known to inhibit ZBTB17 44 and therefore may have adverse effects on survival and hypertrophy in cardiac myocytes. Interestingly, CSRP3 interacts with the aminoterminal POZ domain, which is predicted to interfere with ZBTB17 tetramerization.
An additional layer of complexity is added by the fact that ZBTB17 can be phosphorylated at position S428 by the Akt kinase, which is another important mediator of hypertrophy. 45 This post-translational modification enables the interaction of ZBTB17 with 14-3-3 ŋ and leads to its inactivation, thus avoiding prolonged activation of ZBTB17, which can also have adverse effects. 46 In the Exome Variant Server database, there are 10 T106M variants annotated out of at least 13 006 alleles of European-American and Afro-American origin combined. The Exome Variant Server does not provide data on individual phenotypes, but the frequency for this variant is certainly low and a disease causing or at least modifying role cannot be excluded. Nevertheless, a 2-hit hypothesis whereby a structural perturbation combines with a defect in a ZBTB17-mediated cell survival pathway could also lead to heart failure.
As a result, we expect this variant to impair calcineurin-dependent hypertrophy and being unable to efficiently protect cardiac myocytes from apoptosis. However, this variant may also have specific effects on remodeling and hypertrophy 47 by specifically affecting protein degradation pathways, for example, via the ubiquitin proteasome system, 48 and aside from affecting its interaction with CSRP3 ( Figure 2B ), may specifically interfere with other protein/ protein interactions.
ZBTB17 is a transcription factor that contains the peak association signal (rs10927875) at the replicated 1p36 cardiomyopathy locus. Although other genes in the genomic region of ZBTB17, such as HSPB7 and CLCNKA, have been suggested as possible candidate genes by genome-wide association study, 10,49 ZBTB17 might well be another novel DCMassociated gene. However, except for this report, the effects of ZBTB17 on the cardiovascular system have never been analyzed before. It is interesting to note that HSPB7, which encodes heat shock protein 27, a factor involved in the immediate stress response, CLCNKA, which encodes a K a renal chloride channel involved in the regulation of hypo-osmotic cell stretch, as well as ZBTB17, are all involved in the cellular primary stress response and survival signaling.
At least 50 single genes have been identified as linked to familial DCM, some of which encode proteins of the sarcomere, 50 costamere, Z disc, 3, 4 and nuclear membrane, 51 whereas others function as phosphatases and transcriptional activators (EYA4). 1, 52 Unfortunately, not much is known about how these effects are linked to changes in gene transcription. A recent study found profibrotic gene expression profiles in HCM mouse models and identified transforming growth factor beta 1 (TGFβ1) as the initiating event, but the underlying transcriptional events remained elusive. 53 However, ZBTB17 may well play a role in these genetic circuits. Defective Z disc-mediated survival signaling may also contribute to the DCM phenotype observed in patients carrying truncating Titin (TTN) mutations. 50 In summary, we identify ZBTB17 as a candidate for a new cardiomyopathy gene, which may also be important for heart failure syndromes in general, and suggest that its primary function is to protect cardiac myocytes from apoptosis 5 through modulation of both hypertrophic and cell death pathways ( Figure 4G ).
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